· The chronic neuropsychiatric sequelae of COVID-19 continue to raise questions. A literature review conducted internationally during 2020 by the CNS SARS-CoV-2 Consortium found that varying autoimmune reactions, anosmia, and delirium in COVID-19 patients suggests potentially long-term implications for central nervous system disorders. While immune profiles, age, and activity levels may explain variations in the effects, long-term evaluation will be performed to properly understand post-infectious biological changes in the CNS.
· WHO recommends corticosteroids for patients with severe or critical COVID-19. An international team of researchers associated with the World Health Organization summarized recommendations regarding the use of corticosteroids in COVID-19 patients based on results from 8 RCTs with an n=7184, which found the use of corticosteroids in severely or critically ill patients resulted in a lower 28-day mortality. However, corticosteroid treatment in non-severe COVID-19 patients showed no change in mortality rate. These recommendations provide updated treatment guidelines for COVID-19 patients based on disease severity.